发明名称 |
In Vivo Individualized Systemic Immunotherapeutic Method and Device |
摘要 |
The invention provides an in vivo individualized systemic immunotherapeutic method and device. The method includes, in a non-sequential manner: (1) increasing release amount of tumor antigens at a tumor site; (2) at the tumor site, increasing level of proteins capable of adhering to and/or wrapping the tumor antigens; (3) at the tumor site, increasing level of dedicated antigen-presenting cells involved in immunity, and establishing, between the dedicated antigen-presenting cells and immune effector cells, a close connection capable of activating the immune effector cells; and (4) at the tumor site, increasing level and improving function of the immune effector cells. The steps (1)-(4) each reaches a maximum value at a respective time which overlaps with each other maximally, as well as at a respective site which overlaps with each other maximally. The invention combines oncolytic therapy and immunotherapy, in individualized systemic immunotherapy, and provides significantly improved therapeutic effect. |
申请公布号 |
US2016250292(A1) |
申请公布日期 |
2016.09.01 |
申请号 |
US201615058456 |
申请日期 |
2016.03.02 |
申请人 |
Hangzhou Converd Co., Ltd. |
发明人 |
Hu Fang;Zhao Ronghua;Chen Siyi;Wu Bo;Xia Huiqun;Zheng Yanjun |
分类号 |
A61K38/19;C12N7/00;A61K39/395;C07K16/30;A61K35/761;C07K16/28 |
主分类号 |
A61K38/19 |
代理机构 |
|
代理人 |
|
主权项 |
1. An anti-tumor therapeutic method, which is an in vivo individualized systemic immunotherapeutic method, comprising, in a non-sequential manner, the steps of:
(1) increasing release amount of tumor antigens at a tumor site where treatment is required in a tumor patient; (2) at the tumor site, increasing level of proteins capable of adhering to and/or wrapping the tumor antigens; (3) at the tumor site, increasing level of dedicated antigen-presenting cells involved in immunity, and establishing, between the dedicated antigen-presenting cells and immune effector cells, a connection capable of activating the immune effector cells; and (4) at the tumor site, increasing level of the immune effector cells and improving function thereof, thus establishing a connection between the immune effector cells and target cells, resulting in killing of the target cells; wherein the release amount of the tumor antigens in step (1), the level of the proteins capable of adhering to and/or wrapping the tumor antigens in step (2), the level of the dedicated antigen-presenting cells involved in immunity and the connection between the dedicated antigen-presenting cells and the immune effector cells in step (3), and the level and function of the immune effector cells in step (4) each reaches a maximum value at a respective time which overlaps with each other maximally, as well as at a respective site which overlaps with each other maximally. |
地址 |
Hangzhou CN |